2023
Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood
Matthews T, Rasmussen L, Ambler A, Danese A, Eugen-Olsen J, Fancourt D, Fisher H, Iversen K, Schultz M, Sugden K, Williams B, Caspi A, Moffitt T. Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood. Brain Behavior And Immunity 2023, 115: 727-736. PMID: 37992788, PMCID: PMC11194667, DOI: 10.1016/j.bbi.2023.11.022.Peer-Reviewed Original ResearchConceptsSoluble urokinase plasminogen activator receptorC-reactive proteinSystemic chronic inflammationInterleukin-6Triage StudyMedical patientsChronic inflammationAge 45Social isolationStudy participantsHigher C-reactive proteinNew inflammation markerPopulation-representative birth cohortUrokinase plasminogen activator receptorEnvironmental Risk (E-Risk) Longitudinal Twin StudyHigher median levelsPlasminogen activator receptorDunedin Longitudinal StudyElevated markersSuPAR levelsSystemic inflammationInflammation markersInflammation biomarkersGeneral populationInflammationPlasma Biomarkers and Incident CKD Among Individuals Without Diabetes
Le D, Chen J, Shlipak M, Ix J, Sarnak M, Gutierrez O, Schelling J, Bonventre J, Sabbisetti V, Schrauben S, Coca S, Kimmel P, Vasan R, Grams M, Parikh C, Coresh J, Rebholz C, Consortium C. Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes. Kidney Medicine 2023, 5: 100719. PMID: 37841418, PMCID: PMC10568645, DOI: 10.1016/j.xkme.2023.100719.Peer-Reviewed Original ResearchSoluble urokinase plasminogen activator receptorKidney injury molecule-1Incident chronic kidney diseaseChronic kidney diseaseLevels of kidney injury molecule-1Development of kidney diseaseMonocyte chemoattractant protein-1Kidney diseaseTNFR-2TNFR-1Development of chronic kidney diseaseConcentrations of kidney injury molecule-1Odds of incident chronic kidney diseaseAssociated with incident chronic kidney diseaseTumor necrosis factor receptor 2Urokinase plasminogen activator receptorCases of incident CKDYears of follow-upTumor necrosis factor receptor 1AbstractText Label="PLAIN-LANGUAGE SUMMARYBaseline plasma biomarkersHuman cartilage glycoprotein-39Kidney disease progressionPlasminogen activator receptorChemoattractant protein-1Association of Kidney Tubule Biomarkers With Cardiac Structure and Function in the Multiethnic Study of Atherosclerosis
Wettersten N, Katz R, Greenberg J, Gutierrez O, Lima J, Sarnak M, Schrauben S, Deo R, Bonventre J, Vasan R, Kimmel P, Shlipak M, Ix J. Association of Kidney Tubule Biomarkers With Cardiac Structure and Function in the Multiethnic Study of Atherosclerosis. The American Journal Of Cardiology 2023, 196: 11-18. PMID: 37086700, PMCID: PMC10204591, DOI: 10.1016/j.amjcard.2023.02.031.Peer-Reviewed Original ResearchConceptsPlasma soluble urokinase plasminogen activator receptorSoluble urokinase plasminogen activator receptorKidney tubule injuryCardiac structural abnormalitiesUrokinase plasminogen activator receptorCardiovascular diseasePlasminogen activator receptorLower LVEFTubule injurySystemic inflammationVentricular mass/volume ratioStructural abnormalitiesChitinase-3-like protein 1Activator receptorTwofold greater concentrationCardiac magnetic resonance imagingKidney tubule healthChronic kidney diseaseIncident cardiovascular diseaseGlomerular filtration rateVentricular ejection fractionProtein 1Chemoattractant protein-1Multi-Ethnic StudyAlpha-1-microglobulin
2019
Increased Serum Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta‐Analysis
Lee J, Yang J, Kronbichler A, Eisenhut M, Kim G, Lee K, Shin J. Increased Serum Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta‐Analysis. Journal Of Immunology Research 2019, 2019: 5679518. PMID: 31089477, PMCID: PMC6476117, DOI: 10.1155/2019/5679518.Peer-Reviewed Original ResearchConceptsSoluble urokinase-type plasminogen activator receptorSoluble urokinase-type plasminogen activator receptor levelsPrimary focal segmental glomerulosclerosisUrokinase-type plasminogen activator receptorSerum suPAR levelsPlasminogen activator receptorSuPAR levelsStandardized mean differenceAdult patientsSerum soluble urokinase-type plasminogen activator receptorMeta-analysisHealthy controlsActivator receptorComparison to healthy controlsNewcastle-Ottawa Quality Assessment ScaleHigher suPAR levelsMinimal change diseaseFocal segmental glomerulosclerosisPeriod of diagnosisQuality Assessment ScaleRandom-effects modelRisk of biasNo significant differencePediatric groupChange disease
2016
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View
Kronbichler A, Saleem M, Meijers B, Shin J. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. Journal Of Immunology Research 2016, 2016: 2068691. PMID: 27504461, PMCID: PMC4967695, DOI: 10.1155/2016/2068691.Peer-Reviewed Original ResearchConceptsSoluble urokinase-type plasminogen activator receptorFocal segmental glomerulosclerosisPathogenesis of focal segmental glomerulosclerosisSoluble urokinase-type plasminogen activator receptor levelsSegmental glomerulosclerosisProgression to end-stage renal failureEnd-stage renal failureUrokinase-type plasminogen activator receptorSerum suPAR levelsSoluble urokinase receptorIn Vivo Mouse ModelPlasminogen activator receptorImmunologically active cellsPrimary glomerular disordersSuPAR levelsRenal transplantationRenal failureSecondary causesMouse modelCirculating factorsGlomerular diseaseGlomerular disordersActivator receptorUrokinase receptorHuman studiesRe‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor
Rullo A, Fitzgerald K, Muthusamy V, Liu M, Yuan C, Huang M, Kim M, Cho A, Spiegel D. Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie 2016, 128: 3706-3710. DOI: 10.1002/ange.201510866.Peer-Reviewed Original ResearchAntibody-recruiting small moleculeUrokinase-type plasminogen activator receptorMetastatic cancerPlasminogen activator receptorAntibody-recruiting moleculesCancer cell surface markersCell surface markersImmune responseNon-peptide ligandsTumor growthActivator receptorWeight lossCancer cellsCancerAgent doxorubicinUrokinase receptorReceptorsImmunotherapeuticsSmall moleculesSelective strategy
2013
Vitronectin Inhibits Efferocytosis through Interactions with Apoptotic Cells as well as with Macrophages
Bae H, Tadie J, Jiang S, Park D, Bell C, Thompson L, Peterson C, Thannickal V, Abraham E, Zmijewski J. Vitronectin Inhibits Efferocytosis through Interactions with Apoptotic Cells as well as with Macrophages. The Journal Of Immunology 2013, 190: 2273-2281. PMID: 23345331, PMCID: PMC3577940, DOI: 10.4049/jimmunol.1200625.Peer-Reviewed Original ResearchMeSH KeywordsAcute Lung InjuryAnimalsAntibodiesApoptosisBronchoalveolar Lavage FluidCell CountCoculture TechniquesFemaleLipopolysaccharidesMacrophages, PeritonealMaleMiceMice, Inbred C57BLMice, KnockoutNeutrophilsPhagocytosisPlasminogen Activator Inhibitor 1Receptors, Urokinase Plasminogen ActivatorThymocytesVitronectinConceptsUrokinase-type plasminogen activator receptorApoptotic cellsEffective removal of apoptotic cellsIncubation of apoptotic cellsRemoval of apoptotic cellsPhagocytosis of apoptotic cellsSurface of apoptotic cellsIngest apoptotic cellsApoptotic target cellsPurified vitronectinSoluble urokinase-type plasminogen activator receptorEffects of vitronectinEngulfing phagocytesWild typePlasminogen activator inhibitor-1Plasminogen activator receptorVitronectinInhibit phagocytosisApoptotic neutrophilsActivator inhibitor-1Acute inflammatory conditionsInhibitory effectLPS-induced ALIVitronectin-deficientBronchoalveolar lavage
2009
Structural basis for EGFR ligand sequestration by Argos
Klein D, Stayrook S, Shi F, Narayan K, Lemmon M. Structural basis for EGFR ligand sequestration by Argos. The FASEB Journal 2009, 23: 883.7-883.7. DOI: 10.1096/fasebj.23.1_supplement.883.7.Peer-Reviewed Original ResearchEpidermal growth factor receptorHuman urokinase-type plasminogen activator receptorDiverse developmental processesClamp-like structureEGF-like domainGrowth factor ligandsArgos functionMammalian counterpartsLigand sequestrationEGF-like modulesUrokinase-type plasminogen activator receptorEGF domainsEGF ligandGrowth factor receptorEssential regulatorStructural basisDevelopmental processesStructural homologuesEGFR ligandsFactor ligandHuman cancersPlasminogen activator receptorFactor receptorErbB/Inappropriate activation
1998
Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement
Wang G, Collinge M, Blasi F, Pardi R, Bender J. Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 6296-6301. PMID: 9600959, PMCID: PMC27663, DOI: 10.1073/pnas.95.11.6296.Peer-Reviewed Original ResearchConceptsAU-rich elementsLFA-1 activationMRNA degradationReporter constructsUrokinase plasminogen activator receptorT cell activationCrucial cis-acting elementsCis-acting elementsLymphocyte function-associated antigen-1Integrin lymphocyte function-associated antigen-1Jurkat T cellsLFA-1 engagementUPAR cDNAReceptor-mediated signalingPosttranscriptional regulationTransmembrane signalingReporter mRNAIntegrin engagementCell activationInhibitor 5Adhesion receptorsSecond messengerMessenger RNA levelsPlasminogen activator receptorFunction-associated antigen-1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply